UK markets closed

Xvivo Perfusion AB (publ) (0RKL.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
540.36+11.36 (+2.15%)
At close: 05:34PM BST

Xvivo Perfusion AB (publ)

Gemenskapens gata 9
Mölndal 431 53
46 3 17 88 21 50

Full-time employees152

Key executives

NameTitlePayExercisedYear born
Mr. Christoffer RosenbladChief Executive OfficerN/AN/A1975
Ms. Lena Hagman B.Sc.Chief Operating OfficerN/AN/A1965
Ms. Ylva VihojGlobal Human Resources DirectorN/AN/A1970
Dr. Magnus Nilsson Ph.D.Senior AdvisorN/AN/A1956
Mr. Andreas Wallinder M.D., Ph.D.Chief Medical OfficerN/AN/A1977
Mr. Johan HolmstromChief Commercial OfficerN/AN/A1970
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.


Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Corporate governance

Xvivo Perfusion AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.